Benitec Biopharma Inc. (NASDAQ: BNTC) had its price target raised by analysts at JMP Securities from $10.00 to $16.00. They now have a "market outperform" rating on the stock.
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study [Yahoo! Finance]
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million [Yahoo! Finance]
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million